VANDA PHARMACEUTICALS INC. Royalty Revenue (Deprecated 2018-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) reported Royalty Revenue (Deprecated 2018-01-31) of $6.50 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-02-17.
Discontinued › Income Statement › Other Income
us-gaap:RoyaltyRevenue · last filed 2017-02-17
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $1.58M, a 22.06% decline year-over-year.
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $1.69M, a 13.65% decline year-over-year.
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for the quarter ending 2014-06-30 was $1.54M, a 6.22% decline year-over-year.
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for the quarter ending 2014-03-31 was $1.69M, a 15.66% increase year-over-year.
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for fiscal 2014 was $6.50M, a 8.29% decline from fiscal 2013.
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for fiscal 2013 was $7.09M, a 19.40% increase from fiscal 2012.
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for fiscal 2012 was $5.94M, a 32.52% increase from fiscal 2011.
- VANDA PHARMACEUTICALS INC. royalty revenue (deprecated 2018-01-31) for fiscal 2011 was $4.48M, a 42.66% increase from fiscal 2010.
| Period end | Royalty Revenue (Deprecated 2018-01-31) 3 month | Royalty Revenue (Deprecated 2018-01-31) 6 month | Royalty Revenue (Deprecated 2018-01-31) 9 month | Royalty Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2014-12-31 | $1.58M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $3.27M derived: sum of 2 quarters · filed 2017-02-17 | $4.81M derived: sum of 3 quarters · filed 2017-02-17 | $6.50M 10-K · filed 2017-02-17 |
| 2014-09-30 | $1.69M 10-Q · filed 2015-11-04 | $3.23M derived: sum of 2 quarters · filed 2015-11-04 | $4.92M 10-Q · filed 2015-11-04 | $6.95M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $1.54M 10-Q · filed 2015-07-31 | $3.23M 10-Q · filed 2015-07-31 | $5.26M derived: sum of 3 quarters · filed 2016-02-12 | $7.22M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $1.69M 10-Q · filed 2015-05-07 | $3.72M derived: sum of 2 quarters · filed 2016-02-12 | $5.68M derived: sum of 3 quarters · filed 2016-02-12 | $7.32M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $3.99M derived: sum of 2 quarters · filed 2016-02-12 | $5.63M derived: sum of 3 quarters · filed 2016-02-12 | $7.09M 10-K · filed 2016-02-12 |
| 2013-09-30 | $1.96M 10-Q · filed 2014-10-27 | $3.60M derived: sum of 2 quarters · filed 2014-10-27 | $5.06M 10-Q · filed 2014-10-27 | $6.23M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | $1.64M 10-Q · filed 2014-08-08 | $3.10M 10-Q · filed 2014-08-08 | $4.27M derived: sum of 3 quarters · filed 2015-03-13 | $5.81M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $1.46M 10-Q · filed 2014-05-08 | $2.63M derived: sum of 2 quarters · filed 2015-03-13 | $4.17M derived: sum of 3 quarters · filed 2015-03-13 | $5.87M derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $2.70M derived: sum of 2 quarters · filed 2015-03-13 | $4.40M derived: sum of 3 quarters · filed 2015-03-13 | $5.94M 10-K · filed 2015-03-13 |
| 2012-09-30 | $1.53M 10-Q · filed 2013-11-08 | $3.23M derived: sum of 2 quarters · filed 2013-11-08 | $4.77M 10-Q · filed 2013-11-08 | $6.39M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $1.70M 10-Q · filed 2013-07-31 | $3.23M 10-Q · filed 2013-07-31 | $4.85M derived: sum of 3 quarters · filed 2014-02-25 | $6.07M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $1.53M 10-Q · filed 2013-05-10 | $3.15M derived: sum of 2 quarters · filed 2014-02-25 | $4.37M derived: sum of 3 quarters · filed 2014-02-25 | $5.12M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $2.83M derived: sum of 2 quarters · filed 2014-02-25 | $3.59M derived: sum of 3 quarters · filed 2014-02-25 | $4.48M 10-K · filed 2014-02-25 |
| 2011-09-30 | $1.22M 10-Q · filed 2012-11-08 | $1.97M derived: sum of 2 quarters · filed 2012-11-08 | $2.86M 10-Q · filed 2012-11-08 | $3.37M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-06-30 | $752.00K 10-Q · filed 2012-08-03 | $1.65M 10-Q · filed 2012-08-03 | $2.16M derived: sum of 3 quarters · filed 2013-02-26 | $2.65M derived: sum of 4 quarters · filed 2013-02-26 |
| 2011-03-31 | $895.00K 10-Q · filed 2012-05-09 | $1.41M derived: sum of 2 quarters · filed 2013-02-26 | $1.90M derived: sum of 3 quarters · filed 2013-02-26 | $1.97M derived: sum of 4 quarters · filed 2013-02-26 |
| 2010-12-31 | $511.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $1.00M derived: sum of 2 quarters · filed 2013-02-26 | $1.07M derived: sum of 3 quarters · filed 2013-02-26 | $3.14M 10-K · filed 2013-02-26 |
| 2010-09-30 | $493.00K 10-Q · filed 2011-11-07 | $563.00K derived: sum of 2 quarters · filed 2011-11-07 | $2.63M 10-Q · filed 2011-11-07 | |
| 2010-06-30 | $70.00K 10-Q · filed 2011-08-05 | $2.14M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |